Standard platelet concentrate
Phase 2Biologic
Standard platelet concentrate is one of 11 biologic programs targeting Aortic dissection. It is currently in Phase 2.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Aortic Dissection
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Toradol
JJavelin Pharmaceuticals
Phase 3
Radicava
ShionogiPreclinical
Miraclid
TTechpool Bio-Pharma Co., Ltd.
Preclinical
Xe-133
NNobilis Therapeutics Inc.
Preclinical
Cyklokapron
AAmring
Preclinical
Standard platelet concentrate
JJakob Stensballe, MD, PhD
Phase 2
Thrombosomes
CCellphire Therapeutics, Inc.
Phase 2
Drug
EElro Pharma
Preclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- JJakob Stensballe, MD, PhD